Get intelligentvalue.com

Own it today or select a payment plan

Buy Now$3,879Payment Plan$325/mo

Secured by Stripe

Premium Domain Name

intelligentvalue.com

is available for purchase

51 views

Visitors from

US 54%·

AU 32%·

IN 7%·

GB 2%·

FR 2%

Perfect for

Financial Consulting Technology Startups Educational Services Economic Forecasting E-commerce Solutions Business Analytics Artificial Intelligence Solutions Investment Advisory Strategic Planning Market Research

Unlock the potential of 'intelligentvalue.com', a premium domain that embodies sophistication and expertise in investment advisory and financial consulting. Perfect for businesses in artificial intelligence solutions, market research, and strategic planning, this memorable domain conveys a strong branding message that resonates with clients seeking innovative and data-driven insights. Elevate your presence in the competitive landscape with a digital identity that signifies intelligence, value, and forward-thinking solutions.

Safe & Secure

Protected transactions with Stripe

Fast Transfer

Domain transferred within 24 hours

Flexible Payments

Interest-free payment plans available

3 Small-Cap Stocks in the Doghouse

By: StockStory

April 23, 2025 at 09:04 AM EDT

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

MHK Cover Image

Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a high-risk, high-reward environment due to the lack of reliable analyst price targets.

These trade-offs can cause headaches for even the most seasoned professionals, which is why we started StockStory - to help you separate the good companies from the bad. Keeping that in mind, here are three small-cap stocks to swipe left on and some alternatives you should look into instead.

Mohawk Industries (MHK)

Market Cap: $6.51 billion

Established in 1878, Mohawk Industries (NYSE: MHK) is a leading producer of floor-covering products for both residential and commercial applications.

Why Are We Out on MHK?

Organic sales performance over the past two years indicates the company may need to make strategic adjustments or rely on M&A to catalyze faster growth
Low returns on capital reflect management’s struggle to allocate funds effectively, and its decreasing returns suggest its historical profit centers are aging
Diminishing returns on capital from an already low starting point show that neither management’s prior nor current bets are going as planned

Mohawk Industries’s stock price of $108.45 implies a valuation ratio of 9.9x forward price-to-earnings. Dive into our free research report to see why there are better opportunities than MHK.

Funko (FNKO)

Market Cap: $223.1 million

Boasting partnerships with media franchises like Marvel and One Piece, Funko (NASDAQ: FNKO) is a company specializing in creating and distributing licensed pop culture collectibles.

Why Do We Pass on FNKO?

Sales tumbled by 10.9% annually over the last two years, showing consumer trends are working against its favor
Performance over the past five years shows its incremental sales were much less profitable, as its earnings per share fell by 31.3% annually
Waning returns on capital from an already weak starting point displays the inefficacy of management’s past and current investment decisions

At $4.34 per share, Funko trades at 10.2x forward price-to-earnings. If you’re considering FNKO for your portfolio, see our FREE research report to learn more.

Jazz Pharmaceuticals (JAZZ)

Market Cap: $6.28 billion

Originally founded in 2003 and now headquartered in Ireland following a 2012 tax inversion merger, Jazz Pharmaceuticals (NASDAQGS:JAZZ) develops and markets medicines for sleep disorders, epilepsy, and cancer, with a focus on treatments for patients with limited therapeutic options.

Why Does JAZZ Give Us Pause?

Muted 5.4% annual revenue growth over the last two years shows its demand lagged behind its healthcare peers
Free cash flow margin dropped by 4.1 percentage points over the last five years, implying the company became more capital intensive as competition picked up
ROIC of 3.9% reflects management’s challenges in identifying attractive investment opportunities

Jazz Pharmaceuticals is trading at $106 per share, or 4.6x forward price-to-earnings. Read our free research report to see why you should think twice about including JAZZ in your portfolio.

Stocks We Like More

Market indices reached historic highs following Donald Trump’s presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth.

While this has caused many investors to adopt a "fearful" wait-and-see approach, we’re leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 175% over the last five years.

Stocks that made our list in 2019 include now familiar names such as Nvidia (+2,183% between December 2019 and December 2024) as well as under-the-radar businesses like Sterling Infrastructure (+1,096% five-year return). Find your next big winner with StockStory today for free.

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Symbol	Price	Change (%)
AMZN	254.68	-6.58 (-2.52%)
AAPL	309.47	+3.16 (1.03%)
AMD	512.55	+2.42 (0.48%)
BAC	51.77	+0.26 (0.50%)
GOOG	358.35	-14.23 (-3.82%)
META	602.00	+1.53 (0.25%)
MSFT	451.27	-9.25 (-2.01%)
NVDA	226.01	+1.65 (0.74%)
ORCL	242.82	-5.33 (-2.15%)
TSLA	414.33	-1.55 (-0.37%)